Related Experiment Video
Updated: Sep 14, 2025
07:25
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
13.3K
Experimental models for developing oncolytic virotherapy for metastatic prostate cancer
Ying-Cheng Chen1, Marxa Leão Figueiredo1
1Department of Basic Medical Sciences, College of Veterinary Medicine, Purdue University, West Lafayette, IN, United States.
Frontiers in Immunology
|July 25, 2025
Summary
Oncolytic virotherapy offers a promising approach to combat advanced prostate cancer by utilizing viruses to target tumor cells and enhance immune responses. This review details its potential and evaluation models for treating this aggressive disease.
Area of Science:
- Oncology
- Immunotherapy
- Virology
Background:
- Prostate cancer is a leading cause of death, with advanced metastatic stages having poor survival rates.
- Androgen deprivation therapy (ADT) is standard but often leads to tumor recurrence.
- New therapeutic strategies are urgently needed for aggressive prostate cancer.
Purpose of the Study:
- To review the potential of oncolytic virotherapy for advanced metastatic prostate cancer.
- To explore evaluation models and challenges associated with this treatment modality.
- To provide a comprehensive overview of oncolytic virotherapy in prostate cancer treatment.
Main Methods:
- Review of literature on oncolytic viruses and their mechanisms.
- Discussion of various evaluation models: cell culture, animal models, ex vivo platforms, and clinical trials.
- Analysis of therapeutic gene delivery capabilities of oncolytic viruses.
Main Results:
- Oncolytic virotherapy demonstrates tumor-specific targeting and immune-modulating capabilities.
- It can convert the immunosuppressive tumor microenvironment by increasing immune cell infiltration.
- Viruses can be engineered for enhanced therapeutic gene delivery.
Conclusions:
- Oncolytic virotherapy presents a significant potential for treating advanced prostate cancer.
- Further research and clinical trials are necessary to optimize its application.
- This approach offers a novel strategy to overcome limitations of current therapies.
